ArticleEmerging infectious diseases2016
Leveraging Advances in Tuberculosis Diagnosis and Treatment to Address Nontuberculous Mycobacterial Disease.
Article in Emerging infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Development and internal validation of a LASSO-based clinical prediction model for nontuberculous mycobacterial pulmonary disease versus pulmonary tuberculosis.Frontiers in medicine · 2026Article
- Pediatric Non-Cystic Fibrosis Pulmonary Nontuberculous Mycobacterium Infections: A Global Population Based Study.Pediatric health, medicine and therapeutics · 2025Article
- Genomic-based genotype and drug susceptibility profile ofFrontiers in microbiology · 2025Article
- Toward better cures forClinical microbiology reviews · 2024Review
- Discovery of urinary biosignatures for tuberculosis and nontuberculous mycobacteria classification using metabolomics and machine learning.Scientific reports · 2024Article
- [Research Trends in Nontuberculous Mycobacterial Treatment].Jugan geon-gang gwa jilbyeong · 2024Review
- Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.Nature reviews. Drug discovery · 2024Review
- Contezolid-Containing Regimen Successfully Treated Multiple Drug Resistance Mycobacterium Abscessus Complex Infection of Skin: A Case Report and Literature Review.Infection and drug resistance · 2024Article
- A Novel Inhibitor against the Biofilms of Non-Tuberculous Mycobacteria.Pathogens (Basel, Switzerland) · 2023Article
- Characterization of DNA Gyrase Activity and Elucidation of the Impact of Amino Acid Substitution in GyrA on Fluoroquinolone Resistance in Mycobacterium avium.Microbiology spectrum · 2023Article
- Article
- Clinical Features of Nontuberculous Mycobacterial Pulmonary Disease in the Yangtze River Delta of China: A Single-Center, Retrospective, Observational Study.Tropical medicine and infectious disease · 2023Article
- Efficacy of PBTZ169 and pretomanid against Mycobacterium avium,Frontiers in cellular and infection microbiology · 2023Article
- Metagenomic next-generation sequencing assistance in identifying non-tuberculous mycobacterial infections.Frontiers in cellular and infection microbiology · 2023Article
- Clinical characteristics and imaging features of patients with nontuberculous mycobacteria in a tertiary care center.Journal of clinical tuberculosis and other mycobacterial diseases · 2022Article
- Article
- Doubled Nontuberculous Mycobacteria Isolation as a Consequence of Changes in the Diagnosis Algorithm.Infection and drug resistance · 2022Article
- Anti-Mycobacterial Drug Resistance in Japan: How to Approach This Problem?Antibiotics (Basel, Switzerland) · 2021Review
- Comparative genomic analysis of Mycobacterium intracellulare: implications for clinical taxonomic classification in pulmonary Mycobacterium avium-intracellulare complex disease.BMC microbiology · 2021Article
- Occurrence and risk factors of nontuberculous mycobacteria in tuberculosis-suspected patients in the north of Iran.Iranian journal of microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nontuberculous mycobacteria (NTM), defined as any mycobacterial pathogen other than Mycobacterium tuberculosis or Mycobacterium leprae, are a diverse group of pathogens that collectively cause a substantive but often unappreciated worldwide burden of illness. Although NTMs may cause illness similar to M. tuberculosis, these pathogens generally do not respond to classic tuberculosis (TB) drug regimens, resulting in misdiagnosis and poor treatment, particularly in resource-poor settings. Although a few high-quality epidemiologic surveys have been made on the topic, existing evidence suggests that NTM-associated disease is much more common than previously thought: more common than TB in the industrialized world and likely increasing in prevalence globally. Despite this evidence, these organisms remain markedly understudied, and few international grants support basic science and clinical research. Here we suggest that the considerable efforts in developing new treatments and diagnostics for TB can be harnessed in the fight against NTM-associated illnesses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.